Suven Life Sciences Ltd has secured three product patents, two from Eurasia and one from Canada.
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company and were being developed as therapeutic agents.
They were useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, according to a release issued here on Monday.